Saturday, October 10, 2026

NeuroMetrix Already 5% Up, Almost One Hour Before The Market Open

NeuroMetrix Already 5% Up, Almost One Hour Before The Market Open

(VIANEWS) - The NASDAQ opens in less than one hour and NeuroMetrix's pre-market value is already 5.85% up.

NeuroMetrix's last close was $0.94, 80.13% below its 52-week high of $4.73.

The last session, NASDAQ ended with NeuroMetrix (NURO) jumping 2.03% to $0.94. NASDAQ jumped 1.58% to $14,138.57, after four sequential sessions in a row of gains, on what was an all-around up trend exchanging session.

About NeuroMetrix

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.67.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -21.76%.

Yearly Top and Bottom Value

NeuroMetrix's stock is valued at $0.94 at 08:47 EST, way under its 52-week high of $4.73 and above its 52-week low of $0.89.

Volume

Today's last reported volume for NeuroMetrix is 41690 which is 70.38% below its average volume of 108077.

Earnings Before Interest, Taxes, Depreciation, and Amortization

NeuroMetrix's EBITDA is 5.5.

Moving Average

NeuroMetrix's worth is way under its 50-day moving average of $1.05 and way under its 200-day moving average of $1.60.

More news about NeuroMetrix (NURO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com